Parexel and Sanofi collaborate to advance the use of wearable devices in life science industry
Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficiently.
Parexel International has announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials.
Wearables have the potential to address several challenges related to clinical trials and improve execution by increasing patients’ ability to participate, driving patient engagement, and creating more opportunities for decentralized trial sites. The Parexel-Sanofi collaboration is designed to further explore the potential of patient sensors and wearable devices to remotely collect patient data during clinical trials.
The two companies are jointly leveraging their clinical, scientific, regulatory, logistics and technical expertise, as well as global footprint, to determine how wearables can optimize study performance and accelerate drug development. In particular, the companies are examining how data collected from several wearable devices can be streamlined into a single, scalable data system to provide valuable insights.
Currently, Parexel and Sanofi are collaborating on a pilot study using Parexel’s recently launched patient sensor solution to demonstrate the scientific and medical viability of wearables. In an ongoing single-site study, patient data is being collected remotely and simultaneously via multiple wearable devices. Publication of final study results is expected in the near future.
“We believe the use of wearables to collect data from trial participants represents a breakthrough in the digital transformation within the industry,” said Xavier Flinois, President, Parexel Informatics. “Working with Sanofi, we believe we have a strong opportunity to streamline and automate data collection from multiple devices, collect high-quality data remotely and generate meaningful results, all while reducing burden on patients and sites, as well as lowering costs.”
“Our objective is to demonstrate the relevance of data collected remotely and the overall feasibility of utilizing wearables in clinical trials,” said Lionel Bascles, Global Head of Clinical Sciences and Operations of Sanofi. “Wearables are a core component of Sanofi’s digital trials strategy, and represent an important approach to automate patient processes using the latest technologies to bring new therapies to patients sooner. We are pleased to be collaborating with PAREXEL and leveraging their multi-functional expertise in this area. We are committed to further advancing the potential of this technology.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance